161 related articles for article (PubMed ID: 24535610)
1. Cutaneous and cardiac toxicity of concurrent trastuzumab and adjuvant breast radiotherapy: a single institution series.
Meattini I; Cecchini S; Muntoni C; Scotti V; De Luca Cardillo C; Mangoni M; Bonomo P; Nori J; Casella D; Simoncini R; Orzalesi L; Bianchi S; Livi L
Med Oncol; 2014 Apr; 31(4):891. PubMed ID: 24535610
[TBL] [Abstract][Full Text] [Related]
2. Potential impact of cardiac dose-volume on acute cardiac toxicity following concurrent trastuzumab and radiotherapy.
Cao L; Hu WG; Kirova YM; Yang ZZ; Cai G; Yu XL; Ma JL; Guo XM; Shao ZM; Chen JY
Cancer Radiother; 2014 Mar; 18(2):119-24. PubMed ID: 24642505
[TBL] [Abstract][Full Text] [Related]
3. [Concurrent radiation therapy and dual HER2 blockade in breast cancer: Assessment of toxicity].
Ben Dhia S; Loap P; Loirat D; Vincent-Salomon A; Cao K; Escalup L; Fourquet A; Kirova Y
Cancer Radiother; 2021 Jul; 25(5):424-431. PubMed ID: 33771453
[TBL] [Abstract][Full Text] [Related]
4. Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: acute toxicity analyses from the French multicentric study.
Belkacémi Y; Gligorov J; Ozsahin M; Marsiglia H; De Lafontan B; Laharie-Mineur H; Aimard L; Antoine EC; Cutuli B; Namer M; Azria D
Ann Oncol; 2008 Jun; 19(6):1110-6. PubMed ID: 18344537
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01).
de Azambuja E; Procter MJ; van Veldhuisen DJ; Agbor-Tarh D; Metzger-Filho O; Steinseifer J; Untch M; Smith IE; Gianni L; Baselga J; Jackisch C; Cameron DA; Bell R; Leyland-Jones B; Dowsett M; Gelber RD; Piccart-Gebhart MJ; Suter TM
J Clin Oncol; 2014 Jul; 32(20):2159-65. PubMed ID: 24912899
[TBL] [Abstract][Full Text] [Related]
6. Cardiac toxicity of trastuzumab: experience at the Ghent Unversity Hospital, Belgium.
Lamot C; Rottey S; De Backer T; Van Bortel L; Robays H; Van Belle S; Denys H; Cocquyt V
Acta Clin Belg; 2010; 65(5):300-4. PubMed ID: 21128555
[TBL] [Abstract][Full Text] [Related]
7. Concurrent administration of trastuzumab with locoregional breast radiotherapy: long-term results of a prospective study.
Jacob J; Belin L; Pierga JY; Gobillion A; Vincent-Salomon A; Dendale R; Beuzeboc P; Campana F; Fourquet A; Kirova YM
Breast Cancer Res Treat; 2014 Nov; 148(2):345-53. PubMed ID: 25318926
[TBL] [Abstract][Full Text] [Related]
8. Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.
Dang C; Guo H; Najita J; Yardley D; Marcom K; Albain K; Rugo H; Miller K; Ellis M; Shapira I; Wolff AC; Carey LA; Moy B; Groarke J; Moslehi J; Krop I; Burstein HJ; Hudis C; Winer EP; Tolaney SM
JAMA Oncol; 2016 Jan; 2(1):29-36. PubMed ID: 26539793
[TBL] [Abstract][Full Text] [Related]
9. [Monocentric evaluation of the skin and cardiac toxicities of the concomitant administration of trastuzumab and radiotherapy].
Kirova YM; Caussa L; Granger B; Savignoni A; Dendale R; Campana F; Tournat H; Pierga JY; Fourquet A; Bollet MA
Cancer Radiother; 2009 Jul; 13(4):276-80. PubMed ID: 19447661
[TBL] [Abstract][Full Text] [Related]
10. Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.
Krop IE; Suter TM; Dang CT; Dirix L; Romieu G; Zamagni C; Citron ML; Campone M; Xu N; Smitt M; Gianni L
J Clin Oncol; 2015 Apr; 33(10):1136-42. PubMed ID: 25713436
[TBL] [Abstract][Full Text] [Related]
11. Diastolic Dysfunction Occurs Early in HER2-Positive Breast Cancer Patients Treated Concurrently With Radiation Therapy and Trastuzumab.
Cao L; Cai G; Chang C; Miao AY; Yu XL; Yang ZZ; Ma JL; Zhang Q; Wu J; Guo XM; Chen JY
Oncologist; 2015 Jun; 20(6):605-14. PubMed ID: 25933931
[TBL] [Abstract][Full Text] [Related]
12. Early cardiac toxicity following adjuvant radiotherapy of left-sided breast cancer with or without concurrent trastuzumab.
Cao L; Cai G; Chang C; Yang ZZ; Feng Y; Yu XL; Ma JL; Wu J; Guo XM; Chen JY
Oncotarget; 2016 Jan; 7(1):1042-54. PubMed ID: 26460956
[TBL] [Abstract][Full Text] [Related]
13. Combination of radiotherapy and double blockade HER2 with pertuzumab and trastuzumab for HER2-positive metastatic or locally recurrent unresectable and/or metastatic breast cancer: Assessment of early toxicity.
Ajgal Z; de Percin S; Diéras V; Pierga JY; Campana F; Fourquet A; Kirova YM
Cancer Radiother; 2017 Apr; 21(2):114-118. PubMed ID: 28347625
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.
Tolaney SM; Barry WT; Dang CT; Yardley DA; Moy B; Marcom PK; Albain KS; Rugo HS; Ellis M; Shapira I; Wolff AC; Carey LA; Overmoyer BA; Partridge AH; Guo H; Hudis CA; Krop IE; Burstein HJ; Winer EP
N Engl J Med; 2015 Jan; 372(2):134-41. PubMed ID: 25564897
[TBL] [Abstract][Full Text] [Related]
15. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
Pivot X; Romieu G; Debled M; Pierga JY; Kerbrat P; Bachelot T; Lortholary A; Espié M; Fumoleau P; Serin D; Jacquin JP; Jouannaud C; Rios M; Abadie-Lacourtoisie S; Tubiana-Mathieu N; Cany L; Catala S; Khayat D; Pauporté I; Kramar A;
Lancet Oncol; 2013 Jul; 14(8):741-8. PubMed ID: 23764181
[TBL] [Abstract][Full Text] [Related]
16. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.
Pinto AC; Ades F; de Azambuja E; Piccart-Gebhart M
Breast; 2013 Aug; 22 Suppl 2():S152-5. PubMed ID: 24074778
[TBL] [Abstract][Full Text] [Related]
17. The acute skin and heart toxicity of a concurrent association of trastuzumab and locoregional breast radiotherapy including internal mammary chain: a single-institution study.
Caussa L; Kirova YM; Gault N; Pierga JY; Savignoni A; Campana F; Dendale R; Fourquet A; Bollet MA
Eur J Cancer; 2011 Jan; 47(1):65-73. PubMed ID: 20843680
[TBL] [Abstract][Full Text] [Related]
18. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
Yu AF; Singh JC; Wang R; Liu JE; Eaton A; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Oncologist; 2017 Jun; 22(6):642-647. PubMed ID: 28341761
[TBL] [Abstract][Full Text] [Related]
19. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience.
Guarneri V; Lenihan DJ; Valero V; Durand JB; Broglio K; Hess KR; Michaud LB; Gonzalez-Angulo AM; Hortobagyi GN; Esteva FJ
J Clin Oncol; 2006 Sep; 24(25):4107-15. PubMed ID: 16908934
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and safety of hypofractionated radiotherapy with concurrent anti-HER-2 therapy following breast-conserving therapy for breast cancer.
Dreyfuss AD; Barsky AR; Taunk NK; Clark AS; Freedman GM
Breast J; 2019 Nov; 25(6):1097-1103. PubMed ID: 31254304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
